Non-turberculosis Mycobacterium (NTM) is a growing concern and here is a major unmet need for new medications. It is estimated that ~130,000 patients suffer from NTM in the US and Europe with growth rates approaching 10% annually. There are currently no approved agents for NTM. Elderly and people with compromised immune or lung function are at greatest risk. It is estimated that up to 50% of patients with bronchiectasis may also have active NTM lung infection. Most common treatment for NTM is combination therapy with drugs traditionally used for tuberculosis (TD) which have limited efficacy and high toxicity. NTM is also associated with high healthcare costs and high mortality. It was estimated that the annual cost in the US for 2014 to be $1.7 billion.
Spero is currently developing the first oral novel agent to treat NTM.